John Thomas Burns, Chief Financial Officer of SELLAS Life Sciences Group, Inc., filed a Form 4 on November 20, 2026, disclosing the sale of 3,831 shares of common stock on November 18, 2026, to satisfy tax withholding obligations connected to the vesting of restricted stock units.
Key Highlights
- Reporting person: John Thomas Burns, CFO of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)
- Transaction date: November 18, 2026
- Shares disposed: 3,831 shares of common stock sold at $19.178 per share
- Post-transaction ownership: 558,893 shares of common stock held directly following the transaction
- Transaction code: S (sale), classified as a mandatory "sell to cover" under the issuer's equity incentive plan
- RSU trigger: Vesting was performance-based, connected to the primary endpoint being met in the issuer's Phase 3 REGAL study
SELLAS CFO's Mandatory Share Sale Tied to Phase 3 REGAL Study Milestone
According to the filing, Burns disposed of 3,831 shares of SELLAS Life Sciences Group common stock on November 18, 2026, at a price of $19.178 per share. The transaction was coded "S" and recorded as a disposition (D) in Table I of the Form 4. Following the transaction, Burns directly held 558,893 shares of common stock, the filing disclosed.
The filing's explanation of responses states that the shares sold "represent shares sold to satisfy the Reporting Person's tax withholding obligation in connection with the performance based vesting of certain previously granted restricted stock units upon meeting the primary endpoint in the Issuer's Phase 3 REGAL study." The filing further states that "these sales are mandated as part of the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person."
The Form 4 was signed by Kostantinos Skordalos acting as Power of Attorney for John Burns and was filed on November 20, 2026. No derivative securities transactions were reported in Table II of the filing.
What Was Disclosed
SELLAS Life Sciences Group CFO John Thomas Burns reported a mandatory sale of 3,831 shares at $19.178 on November 18, 2026, to cover tax withholding on RSUs that vested upon meeting the primary endpoint in the Phase 3 REGAL study, leaving him with 558,893 directly held shares.



Please wait processing your request...